M&A Consultant – Pharmaceutical Industry

Request Expert / Similar Expert

Click “request expert” for a free initial screening call with this expert or a similar expert regarding your expert consulting needs

Summary

This M&A Consultant and divestiture expert is a high-performing, self-motivated, and team-oriented M&A leader with a proven history building value, and trusted relationships, through meaningful corporate strategy and deal execution. He’s a challenge seeker and key contributor that not only excels at finding opportunities and solving problems, but has also demonstrated a high-calibur performance at top-tier institutions and employers. Beyond his positive and relentlessly driven personality, his success also stems from his diverse and high-quality skill set across engineering, finance, securities analysis, management consulting, and all aspects of both buy- and sell-side M&A execution.  His background in M&A consulting provides a strong foundation in finding and doing the right deals, leading large diligence teams and executing the right way, developing the right materials, and being the right “partner” to both internal and external stakeholders.  These attributes have led to his leadership across ~20 M&A transactions worth $15+ Billion in value, including both public and private companies ranging from single asset innovative technology companies to large, commercial-stage, manufacturing companies with multiple development and production sites.   

Highlights 

Relevant Accomplishments 

• Supported Johnson & Johnson’s M&A team directly out of grad school, designed and built Monte-Carlo simulation DCF valuation models 
• Selected to join Lazard’s Capital Markets team (Institutional Investor #4 ranked) out of large candidate pool based on high-quality model, writing, and presentation samples 
• Led the identification, evaluation, and M&A diligence of a $100M acquisition declined by BOD (value of that company today is $7 Billion) 
• Built an M&A Advisory group within a multinational consulting firm  
• Leveraged M&A skill set to growth a consulting practice from 30 to 145 people (3 acquisitions) 
• Pioneered a streamlined approach to specialty pharma and CDMO M&A in 2009-2011, as demonstrated by Valeant’s 200% increase in stock price during his M&A leadership 
• Advised and led the $10M acquisition of PE-owned supplement business that subsequently sold for ~$300M (30x return) 
• Led the full range of buy-side M&A activity, including post-merger integration and oversight of the IMO team, for two simultaneous large pharma subsidiary spin-outs ($450M and $525M) leading to incremental revenue of 25% in one-quarter 
• Advised and led all pre-integration M&A activities including cross-functional diligence, valuation and synergy analysis, deal structuring and proposal development for a client’s $2.8B buy-side opportunity. Worked closely with client’s C-suite to outline platform value and subsequent long-term synergy value.  
• Advised and led all pre-integration M&A activities including cross-functional diligence, valuation and synergy analysis, deal structuring and proposal development for a client’s $11B buy-side opportunity. Spearheaded the revenue and EBITDA growth profile exercise which led to a subsequent $32 billion sale process (M&A support role).  
• Advised and led all pre-integration M&A activities including cross-functional diligence, valuation and synergy analysis, deal structuring and proposal development for a client’s $1.3B buy-side opportunity.  

Roles

• Founder & Managing Director, BioVerity Partners LLC (M&A Advisory & Consulting) 
• Advising range of M&A focused clients ranging from manufacturing divestitures to early stage technology companies (both sell- and buy-side) 
• Closing the sale of a $200M solid oral dose manufacturing facility, leveraged strong network including healthcare and technology driven real estate fund buyers 
• Vice President, Impel Pharmaceuticals (previously public, sold to Woodward Pharma) 
• Led all M&A and strategic initiatives (both sell- and buy-side); generated in-bound LOI within 5 months 
• Vice President, OncoSec Medical (previously public) 
• Led all M&A and strategic initiatives (both sell-side and reverse merger); generated merger LOI within 6 months; key member of executive team 
• Senior Director, Adare Pharmaceuticals (PE-backed manufacturing company, sold to new PE) 
• Led all M&A and strategic initiatives; divested manufacturing facility; solely responsible for acquistion with 30X ROI ($10M acquisition led to ~$300M divestiture) 
• Director, Valeant Pharmaceuticals (public manufacturing & sales) 
• Led all M&A initiatives during 2010 – 2011 inorganic growth period (public shares increased from ~$15/share to ~$45/share for 2x ROI during M&A tenure

Request Expert / Similar Expert

Click “request expert” for a free initial screening call with this expert or a similar expert regarding your expert consulting needs